Big Pharma Using 'Citizen' Petitions to Slow Generics

, Corporate Counsel

   | 0 Comments

The citizen petition process gives ordinary citizens a way to voice safety concerns about a drug. But Robin Feldman, a law professor at the University of California, Hastings College of the Law, says that the process "has been hijacked" by the drug industry to delay generic competition.

This premium content is reserved for CC Corporate Counsel subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202773979968

Thank you!

This article's comments will be reviewed.